|
WO2009132058A2
(en)
*
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
EP3974453A3
(en)
*
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术（上海）有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
PT3415531T
(pt)
*
|
2011-05-27 |
2023-09-12 |
Glaxo Group Ltd |
Proteínas de ligação a bcma (cd269/tnfrsf17
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
CA2869562C
(en)
*
|
2012-04-11 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
US10189906B2
(en)
|
2012-11-01 |
2019-01-29 |
Max-Delrück-Centrum Für Molekulare Medizin |
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6636803B2
(ja)
*
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
MX2016010128A
(es)
|
2014-02-07 |
2017-02-02 |
Univ Mcmaster |
Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
|
|
EP3123169B1
(en)
|
2014-03-26 |
2022-05-04 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Flattop (fltp) is a novel biomarker for beta cell maturation
|
|
CN106536549B
(zh)
|
2014-04-25 |
2020-01-17 |
蓝鸟生物公司 |
Mnd启动子嵌合抗原受体
|
|
US10144782B2
(en)
*
|
2014-04-30 |
2018-12-04 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Humanized antibodies against CD269 (BCMA)
|
|
ES2846811T3
(es)
|
2014-06-06 |
2021-07-29 |
Bluebird Bio Inc |
Composiciones de células T mejoradas
|
|
CN106687483B
(zh)
|
2014-07-21 |
2020-12-04 |
诺华股份有限公司 |
使用人源化抗-bcma嵌合抗原受体治疗癌症
|
|
BR112017001385B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc. |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
JP6706244B2
(ja)
*
|
2014-07-24 |
2020-06-03 |
ブルーバード バイオ， インコーポレイテッド |
Ｂｃｍａキメラ抗原受容体
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
KR102476226B1
(ko)
|
2014-08-05 |
2022-12-12 |
아폴로믹스 인코포레이티드 |
항-pd-l1 항체
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
SI3226897T1
(sl)
*
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
|
|
EP4310097A3
(en)
|
2014-12-05 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
SI3628687T1
(sl)
|
2014-12-12 |
2021-12-31 |
2Seventy Bio, Inc. |
BCMA himerni antigenski receptorji
|
|
PE20171653A1
(es)
|
2015-04-13 |
2017-11-13 |
Pfizer |
Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
|
|
CN114773476A
(zh)
|
2015-04-13 |
2022-07-22 |
辉瑞公司 |
治疗性抗体和它们的用途
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
EP3324965A4
(en)
*
|
2015-07-24 |
2019-07-03 |
Oncotracker, Inc. |
MODULATORS OF GAMMA-SECRETASE FOR THE TREATMENT OF MALFUNCTIONS OF THE IMMUNE SYSTEM
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
SI3331910T1
(sl)
|
2015-08-03 |
2020-07-31 |
Engmab Sarl |
Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
|
|
PE20180795A1
(es)
|
2015-08-17 |
2018-05-09 |
Janssen Pharmaceutica Nv |
Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
|
|
EP3858388A1
(en)
|
2015-09-28 |
2021-08-04 |
Regents of the University of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
|
KR20190008171A
(ko)
*
|
2015-11-13 |
2019-01-23 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항-bcma 폴리펩티드 및 단백질
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
WO2017123741A1
(en)
|
2016-01-12 |
2017-07-20 |
Institute For Myeloma & Bone Cancer Research |
Improved methods for monitoring immune status of a subject
|
|
KR20180103084A
(ko)
|
2016-02-03 |
2018-09-18 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
CN108778329B
(zh)
*
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3430058A4
(en)
|
2016-03-15 |
2019-10-23 |
Generon (Shanghai) Corporation Ltd. |
MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
|
|
WO2017173384A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
|
SI3436079T1
(sl)
|
2016-04-01 |
2022-01-31 |
Kite Pharma, Inc. |
Himerni antigen in T celični receptorji ter način uporabe
|
|
CN109414455B
(zh)
|
2016-04-01 |
2023-01-20 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
|
AU2017281034B2
(en)
|
2016-06-21 |
2024-03-14 |
Teneobio, Inc. |
CD3 binding antibodies
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018052503A1
(en)
|
2016-09-14 |
2018-03-22 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
|
BR112019008426A2
(pt)
|
2016-11-02 |
2019-09-03 |
Engmab Sarl |
anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP4215548A1
(en)
|
2016-12-21 |
2023-07-26 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
CA3052779A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
EP3589655B1
(en)
|
2017-02-28 |
2022-10-26 |
Affimed GmbH |
Tandem-diabody for cd16a-directed nk-cell engagement
|
|
CN110475790A
(zh)
|
2017-03-24 |
2019-11-19 |
全药工业株式会社 |
抗IgM/B细胞表面抗原双特异性抗体
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CA3061945A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
WO2018231944A1
(en)
|
2017-06-13 |
2018-12-20 |
Berenson James R |
Diagnostic, prognostic, and monitoring methods for solid tumor cancers
|
|
WO2018231949A1
(en)
|
2017-06-14 |
2018-12-20 |
Dana-Farber Cancer Institute, Inc. |
B-cell maturation antigen (bcma)-directed nanoparticles
|
|
WO2018237037A2
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
|
|
AU2018288803A1
(en)
|
2017-06-20 |
2020-02-06 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
CR20200100A
(es)
|
2017-08-01 |
2020-05-09 |
Medimmune Llc |
Conjugado de anticuerpo monoclonal contra bcma -fármaco
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CA3075399A1
(en)
|
2017-09-13 |
2019-03-21 |
Teneobio, Inc. |
Heavy chain antibodies binding to ectoenzymes
|
|
US11447559B2
(en)
|
2017-09-29 |
2022-09-20 |
Mogam Institute For Biomedical Research |
Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
|
|
JP7227630B2
(ja)
|
2017-10-12 |
2023-02-22 |
マックマスター ユニバーシティー |
Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
|
|
TWI829655B
(zh)
|
2017-10-18 |
2024-01-21 |
瑞士商諾華公司 |
用於選擇性蛋白質降解的組合物及方法
|
|
KR20200116077A
(ko)
|
2017-11-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
WO2019090364A1
(en)
|
2017-11-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
JP2021502979A
(ja)
|
2017-11-15 |
2021-02-04 |
ノバルティス アーゲー |
Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
|
|
KR20200096253A
(ko)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
Bcma-표적화 키메라 항원 수용체, 및 이의 용도
|
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
|
BR112020011144A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
formulação de meio livre de soro para o cultivo de células e métodos de uso da mesma
|
|
SG11202005880XA
(en)
|
2017-12-22 |
2020-07-29 |
Teneobio Inc |
Heavy chain antibodies binding to cd22
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
JP6968389B2
(ja)
|
2018-02-01 |
2021-11-17 |
南京馴鹿医療技術有限公司 |
Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用
|
|
CN116041516A
(zh)
*
|
2018-02-01 |
2023-05-02 |
信达生物制药(苏州)有限公司 |
全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
|
|
TWI728309B
(zh)
|
2018-02-01 |
2021-05-21 |
大陸商南京馴鹿醫療技術有限公司 |
一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
CN112119099A
(zh)
|
2018-03-02 |
2020-12-22 |
Cdr-生物科技股份有限公司 |
三特异性抗原结合蛋白
|
|
KR20200143436A
(ko)
|
2018-04-13 |
2020-12-23 |
아피메트 게엠베하 |
Nk 세포 결합 항체 융합 구조체
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
WO2019241426A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
WO2020004937A1
(ko)
*
|
2018-06-26 |
2020-01-02 |
주식회사 티에스디라이프사이언스 |
항-bcma 항체-약물 접합체 및 그 용도
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
MX2021000488A
(es)
|
2018-07-19 |
2021-04-12 |
Regeneron Pharma |
Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos.
|
|
CN116769032A
(zh)
|
2018-07-20 |
2023-09-19 |
坦尼奥第二公司 |
与cd19结合的重链抗体
|
|
US20210163893A1
(en)
|
2018-08-09 |
2021-06-03 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
US20210230671A1
(en)
|
2018-08-09 |
2021-07-29 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
|
EP3844267A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN112955467A
(zh)
|
2018-10-26 |
2021-06-11 |
特尼奥生物股份有限公司 |
与cd38结合的重链抗体
|
|
BR112021008133A2
(pt)
|
2018-10-31 |
2021-10-05 |
Juno Therapeutics Gmbh |
Métodos para seleção e estimulação de células e aparelhos para os mesmos
|
|
WO2020092848A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
WO2020092854A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
AU2019377854A1
(en)
|
2018-11-08 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
|
SG11202009283QA
(en)
|
2019-01-16 |
2020-10-29 |
Caribou Biosciences Inc |
Humanized bcma antibody and bcma-car-t cells
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
JOP20210253A1
(ar)
|
2019-04-05 |
2023-01-30 |
Teneobio Inc |
أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2020224606A1
(zh)
|
2019-05-07 |
2020-11-12 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
EP3964238A4
(en)
|
2019-05-07 |
2022-09-14 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
MANIPULATED IMMUNE CELL TARGETING BCMA AND USE THEREOF
|
|
JP2022537931A
(ja)
|
2019-06-14 |
2022-08-31 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
CA3146341A1
(en)
|
2019-07-30 |
2021-02-04 |
Aaron L. Kurtzman |
Bispecific anti lrrc15 and cd3epsilun antibudies
|
|
KR20220068984A
(ko)
*
|
2019-07-30 |
2022-05-26 |
상하이 한서 바이오메디컬 컴퍼니 리미티드 |
항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
|
|
CN112409482B
(zh)
*
|
2019-08-20 |
2022-08-26 |
杭州尚健生物技术有限公司 |
Bcma抗体
|
|
CN114401989B
(zh)
*
|
2019-09-20 |
2024-02-09 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
WO2021132746A1
(en)
*
|
2019-12-24 |
2021-07-01 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
AU2020405183A1
(en)
|
2019-12-18 |
2022-06-09 |
TeneoFour, Inc. |
Heavy chain antibodies binding to CD38
|
|
KR20220012314A
(ko)
*
|
2020-01-03 |
2022-02-03 |
살루브리스 (청두) 바이오테크 코., 리미티드 |
Bcma에 결합하는 항체 및 그의 용도
|
|
JP2023511274A
(ja)
|
2020-01-14 |
2023-03-17 |
シンセカイン インコーポレイテッド |
Ｉｌ２オルソログおよび使用法
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
CN113248611A
(zh)
*
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CA3173394A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
EP4142723A2
(en)
|
2020-04-28 |
2023-03-08 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
TW202330622A
(zh)
|
2020-04-29 |
2023-08-01 |
美商泰尼歐生物公司 |
具有經修飾重鏈恆定區之多特異性重鏈抗體
|
|
BR112022021690A2
(pt)
|
2020-04-29 |
2022-12-20 |
Teneobio Inc |
Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
|
|
CA3182697A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
JP2023528215A
(ja)
|
2020-05-13 |
2023-07-04 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
|
WO2022006316A1
(en)
|
2020-06-30 |
2022-01-06 |
Teneobio, Inc. |
Multi-specific antibodies binding to bcma
|
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
WO2022037528A1
(zh)
*
|
2020-08-20 |
2022-02-24 |
正大天晴药业集团股份有限公司 |
结合bcma的单可变结构域及抗原结合分子
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
CA3191224A1
(en)
|
2020-10-16 |
2022-04-21 |
Shenda GU |
Multispecific binding compounds that bind to pd-l1
|
|
WO2022094245A1
(en)
|
2020-10-30 |
2022-05-05 |
Vor Biopharma, Inc. |
Compositions and methods for bcma modification
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
|
EP4271404A2
(en)
|
2020-12-31 |
2023-11-08 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating car-t activity
|
|
CN112321713B
(zh)
*
|
2020-12-31 |
2021-05-25 |
北京艺妙神州医药科技有限公司 |
一种抗bcma的抗体及其应用
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
CR20230398A
(es)
|
2021-02-16 |
2023-11-15 |
Janssen Pharmaceutica Nv |
Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
|
|
CN117500835A
(zh)
|
2021-02-25 |
2024-02-02 |
特尼奥生物股份有限公司 |
抗psma抗体及car-t结构
|
|
WO2022183101A1
(en)
|
2021-02-26 |
2022-09-01 |
Teneobio, Inc. |
Anti-muc1-c antibodies and car-t structures
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
JPWO2022196719A1
(pt)
|
2021-03-17 |
2022-09-22 |
|
|
|
KR20230158573A
(ko)
|
2021-03-22 |
2023-11-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
바이러스 벡터 입자의 효력을 평가하는 방법
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
CR20230474A
(es)
|
2021-04-06 |
2023-11-23 |
Teneobio Inc |
Anticuerpos anti-cd19 y estructuras car-t
|
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
|
WO2022221737A1
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
T cell therapy in patients who have had prior stem cell transplant
|
|
KR20230171468A
(ko)
|
2021-04-16 |
2023-12-20 |
셀진 코포레이션 |
Bcma-지시된 t 세포 요법과의 조합 요법
|
|
CN117337303A
(zh)
|
2021-04-16 |
2024-01-02 |
特尼奥生物股份有限公司 |
抗cd20抗体及car-t结构
|
|
TW202309294A
(zh)
|
2021-04-27 |
2023-03-01 |
瑞士商諾華公司 |
病毒載體生產系統
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
BR112023024231A2
(pt)
|
2021-05-19 |
2024-01-30 |
Sana Biotechnology Inc |
Células t primárias rhd negativas hipoimunogênicas
|
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells that include transgenic HLA-E or HLA-G
|
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
WO2023288267A1
(en)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向ｃｄ４之病毒載體之用途
|
|
CA3227613A1
(en)
|
2021-08-11 |
2023-02-16 |
William Dowdle |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
CA3229746A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
TW202323281A
(zh)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
|
TW202342757A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科附著醣蛋白
|
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
CN114276452A
(zh)
*
|
2021-12-29 |
2022-04-05 |
源道隆（苏州）医学科技有限公司 |
可结合bcma的纳米抗体及其应用
|
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023152747A1
(en)
|
2022-02-09 |
2023-08-17 |
Hadasit Medical Research Services And Development Ltd. |
Anti-bcma car to target immune-related disorders, compositions and method thereof
|
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023196997A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
EP4311579A1
(en)
*
|
2022-07-29 |
2024-01-31 |
Association Française contre les Myopathies |
B cell-specific mab-sirna conjugates improve myasthenia
|
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|